Geninus Inc. (389030)

Overview

GENINUS Inc. is a forward-thinking bioinformation analysis company based in Seoul, South Korea, that was founded in 2018. The company is at the forefront of the biotechnology industry, dedicating its efforts to the research and development, manufacture, and sale of next-generation sequencing (NGS)-based genome analysis solutions. Its innovative approach aims to contribute significantly to healthcare by focusing on precision medicine and genetic research. GENINUS Inc. caters to a diverse clientele, including hospitals, pharmaceutical companies, and researchers, offering cutting-edge solutions to complex genetic and genomic inquiries.

Products and Services

• CancerSCAN:

  This NGS-based cancer genome diagnosis solution is designed to offer comprehensive genetic insights into various types of cancer, enabling personalized treatment plans based on the genetic makeup of an individual's cancer.

• LiquidSCAN:

  A liquid biopsy NGS test that allows for the non-invasive detection of cancer by analyzing circulating tumor DNA in the bloodstream. This innovative approach facilitates early cancer detection and monitoring of treatment response.

• Celinus:

  An ultra-precise single-cell analysis solution that enables researchers and clinicians to examine the genetic heterogeneity within a cell population, providing groundbreaking insights in cancer research, tumor evolution, and therapy resistance.

• HealthSCAN:

  A genetic test service that assesses a person's predisposition to certain health conditions, empowering individuals with actionable insights into their genetic health risks and promoting preventative healthcare measures.

• WithMe:

  A service that analyzes the characteristics of gut bacteria and its association with the risk of developing chronic diseases. This solution emphasizes the importance of gut microbiota in maintaining overall health and preventing disease.

• OncoSTATION:

  An automated clinical genome information analysis solution that streamlines the process of interpreting genomic data in a clinical setting. OncoSTATION aids in the fast and accurate identification of actionable genetic mutations, supporting the implementation of precision medicine in oncology.